Tuesday, October 6 and Wednesday, October 7, Evrys Bio will be represented at the premier mid-Atlantic biotech and pharmaceutical partnering conference.  Dr. Lillian Chiang, CEO and Dana Fowlkes, CBO will be representing Evrys Bio.  This virtual conference has been extended to a total of four days to permit more opportunities for one on one partnering discussions.  Evrys Bio is seeking potential partners to participate in the clinical development of lead candidates in serious respiratory diseases and viral hepatitis.

For more information go HERE

Pennsylvania Biotechnology Center of Bucks County is once again in the spotlight, this time as the recipient of more than $1 million in state grants to help with research in pursuing a treatment and vaccine for COVID-19.

Of 23 state awards, the biotechnology center, located next to the Doylestown Airport in Buckingham, received four grants, bringing in $1.1 million of the $10 million statewide allocation. The money will help support the biotech center’s renovation plans, which will add research and training labs, more than 100 new jobs and new offices for COVID-19 research and development.

Two grants will go to scientists developing potential COVID-19 treatments at the Baruch S. Blumberg Institute at the biotech center and a hub for virology research for more than 17 years.

Another $322,000 grant is going to one of the center’s member companies, Evrys Bio. The company’s scientists are developing host-targeted antiviral drugs that can block the growth of different respiratory viruses including coronaviruses, and that can provide a high barrier to drug resistance.

Lillian Chiang, CEO of Evrys Bio, said her company’s goal is to develop broad-spectrum drugs that treat multiple viruses causing respiratory disease, rather than a single virus.

“We are grateful for these funds from the state of Pennsylvania that will enable us to extend our testing to SARS-CoV2, speeding our efforts to contribute to a COVID-19 solution,” said Chiang.

The biotechnology center, which opened in 2006, has more than 70 member companies, 41 of which have offices or labs in the facility.

More information

Governor Tom Wolf announced that 23 awardees will receive $10 million in grant funding through the COVID-19 Vaccines, Treatments and Therapies (CV-VTT) program to support the rapid advancement of vaccines, treatments and therapies by qualified biotechnology entities in response to the COVID-19 pandemic.

Evrys Bio was awarded over $300,000 to develop treatments for virus caused respiratory infections.  To date, Evrys Bio has seen excellent activity of certain proprietary pre-clinical leads against both corona viruses and influenza viruses.

Press Release

July 22, 2020:  In response to emergency research funding for COVID-19, the supplement extends testing of Evrys broad-spectrum antivirals to coronaviruses including SRAS-CoV-2. ABSTRACT

November 21, 2019 – Evrys Bio President & CEO, Lillian Chiang gives oral presentation, “Host Sirtuin-2 Protein (SIRT2) – A Validated Target for Broadly-Effective Antiviral Small-Molecule Drugs,” at the 2019 Chemical and Biological Defense Science & Technology (CBD S&T) Conference Cincinnati, OH.   See the PowerPoint Presentation

Evrys Bio awarded Phase II SBIR grant from the NIH National Institute for Allergy and Infectious Disease titled, “A Single Antiviral to Treat Multiple Opportunistic Infections” (5R44AI11407902).  Details are HERE